Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer

Nivolumab, an immune checkpoint blocker, has been approved for advanced gastric cancer (GC), but predictive factors of nivolumab’s efficacy in patients with GC, especially immune cells such as tissue-resident memory T cells or those forming tertiary lymphoid structures (TLS), remain unclear. Tissue...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Takuya, Tanaka, Hiroaki, Deguchi, Sota, Yamakoshi, Yoshihito, Miki, Yuichiro, Yoshii, Mami, Tamura, Tatsuro, Toyokawa, Takahiro, Lee, Shigeru, Muguruma, Kazuya, Ohira, Masaichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741034/
https://www.ncbi.nlm.nih.gov/pubmed/34995329
http://dx.doi.org/10.1371/journal.pone.0262455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741034/
https://www.ncbi.nlm.nih.gov/pubmed/34995329
http://dx.doi.org/10.1371/journal.pone.0262455

Ejemplares similares